Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 8, Pages 2204
Publisher
MDPI AG
Online
2023-04-10
DOI
10.3390/cancers15082204
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
- (2023) Rajesh Pradhan et al. Pharmaceutics
- Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
- (2023) Hatem Soliman et al. NATURE MEDICINE
- Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using In Vitro and In Vivo Models
- (2022) Arindam Pramanik et al. ACS Applied Materials & Interfaces
- Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
- (2022) Yi Xiao et al. CELL RESEARCH
- Immunotherapy for early triple negative breast cancer: research agenda for the next decade
- (2022) Paolo Tarantino et al. npj Breast Cancer
- PARP inhibition in breast cancer: progress made and future hopes
- (2022) Nadine Tung et al. npj Breast Cancer
- Immunotherapy in triple-negative breast cancer: A literature review and new advances
- (2022) Guillermo Arturo Valencia et al. World Journal of Clinical Oncology
- Applicability of ESMO-MCBS and ESCAT for molecular tumor boards
- (2022) Ladislaia Wolff et al. Memo-Magazine of European Medical Oncology
- Hyaluronic-Acid-Tagged Cubosomes Deliver Cytotoxics Specifically to CD44-Positive Cancer Cells
- (2022) Arindam Pramanik et al. MOLECULAR PHARMACEUTICS
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
- (2022) Javier Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends
- (2022) Karen Pinilla et al. Frontiers in Oncology
- Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
- (2022) Rita Ribeiro et al. Frontiers in Molecular Biosciences
- Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison
- (2022) Riccardo Lobefaro et al. Clinical Breast Cancer
- Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
- (2022) Yara Abdou et al. npj Breast Cancer
- Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
- (2021) Romualdo Barroso-Sousa et al. BIODRUGS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2021) Binghe Xu et al. LANCET ONCOLOGY
- BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
- (2021) Yu Li et al. Scientific Reports
- Precision medicine in breast cancer: from clinical trials to clinical practice
- (2021) Edoardo Crimini et al. CANCER TREATMENT REVIEWS
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
- (2021) P. Schmid et al. ANNALS OF ONCOLOGY
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
- (2021) Fokhrul Hossain et al. Cancers
- The emerging role of immune checkpoint inhibitors for the treatment of breast cancer
- (2021) Frederick M. Howard et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
- (2021) Giacomo Barchiesi et al. Frontiers in Oncology
- Clinical Trials of Oncolytic Viruses in Breast Cancer
- (2021) Mary E. Carter et al. Frontiers in Oncology
- Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
- (2021) Desh Deepak Singh et al. Biomedicines
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT inhibition improves OS in TNBC
- (2020) David Killock Nature Reviews Clinical Oncology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- Personalized Medicine: Recent Progress in Cancer Therapy
- (2020) Valentina Gambardella et al. Cancers
- Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers
- (2020) Diego Fernández-Lázaro et al. Diagnostics
- Novel HER2‐targeted therapies for HER2‐positive metastatic breast cancer
- (2020) Siddharth Kunte et al. CANCER
- Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
- (2020) Yi-Zhou Jiang et al. CELL RESEARCH
- Pharmacological disruption of the Notch transcription factor complex
- (2020) Rajwinder Lehal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
- (2020) Salvatore Del Prete et al. Oncotarget
- Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
- (2020) Linda Anna Michelle Kulka et al. Frontiers in Cell and Developmental Biology
- Antibody-Drug Conjugates in Metastatic Triple Negative Breast Cancer: A Spotlight on Sacituzumab govitecan, Ladiratuzumab vedotin, and Trastuzumab deruxtecan
- (2020) Julia E. McGuinness et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
- (2020) Qin Wu et al. Nature Communications
- Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
- (2020) Gagan K. Gupta et al. Cancers
- CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
- (2020) Debora de Melo Gagliato et al. Cancers
- Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
- (2020) Paolo Tarantino et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Targeting Notch in oncology: the path forward
- (2020) Samarpan Majumder et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC
- (2019) Ling Wu et al. Scientific Reports
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2019) Sherene Loi et al. CLINICAL CANCER RESEARCH
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- (2019) T Bachelot et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
- (2019) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer
- (2019) Hyun Jee Han et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype
- (2019) M. V. Giuli et al. Journal of Oncology
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
- (2019) J Cortés et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
- (2018) L. Gerratana et al. CANCER TREATMENT REVIEWS
- Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model
- (2018) Walhan Alshaer et al. JOURNAL OF CONTROLLED RELEASE
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- The Limits and Potential Future Applications of Personalized Medicine to Prevent Complex Chronic Disease
- (2018) Sharon Horesh Bergquist et al. PUBLIC HEALTH REPORTS
- Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies
- (2018) Dorota Kwapisz Breast Cancer
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers
- (2018) Kevin J. Hamblett et al. CANCER RESEARCH
- Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
- (2018) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
- (2018) Teresa Gamucci et al. CANCER BIOLOGY & THERAPY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways
- (2018) Fokhrul Hossain et al. Frontiers in Oncology
- Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
- (2017) Xin Li et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Tipping Point for Measurement-Based Care
- (2017) John C. Fortney et al. PSYCHIATRIC SERVICES
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
- (2017) Patrizia Vici et al. Oncotarget
- LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)
- (2017) J. Baselga et al. ANNALS OF ONCOLOGY
- Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer
- (2017) Tomas Pascual et al. PLoS One
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
- (2016) G. Jerusalem et al. ANNALS OF ONCOLOGY
- Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors
- (2016) YI-LONG WU et al. ANTICANCER RESEARCH
- Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
- (2016) Erik Hilborn et al. BRITISH JOURNAL OF CANCER
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
- (2016) Kenji Tamura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data
- (2016) Neelima Vidula et al. Clinical Breast Cancer
- Cubosomes: remarkable drug delivery potential
- (2016) Zahra Karami et al. DRUG DISCOVERY TODAY
- RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
- (2016) Robert A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
- (2016) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolomics enables precision medicine: “A White Paper, Community Perspective”
- (2016) Richard D. Beger et al. Metabolomics
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients
- (2016) Sara M. Tolaney et al. ONCOLOGIST
- Precision medicine in pediatric oncology: Lessons learned and next steps
- (2016) Rajen J. Mody et al. PEDIATRIC BLOOD & CANCER
- Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Xue Li et al. Targeted Oncology
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer
- (2016) Lauren L. Siewertsz van Reesema et al. EBioMedicine
- Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
- (2015) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population
- (2015) Neil E. Bhola et al. CANCER RESEARCH
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
- (2015) Christine S. Walsh GYNECOLOGIC ONCOLOGY
- A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
- (2015) Joanne W. Chiu et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
- (2015) Sara M. Tolaney et al. INVESTIGATIONAL NEW DRUGS
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Precision medicine for metastatic breast cancer—limitations and solutions
- (2015) Monica Arnedos et al. Nature Reviews Clinical Oncology
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- A New Initiative on Precision Medicine
- (2015) Francis S. Collins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6
- (2015) Yu-Chun Hsiao et al. Oncotarget
- The Evolving Landscape of HER2 Targeting in Breast Cancer
- (2015) Mark M. Moasser et al. JAMA Oncology
- Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation
- (2015) Tri-Hung Nguyen et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
- (2015) Giuseppina Rosaria Rita Ricciardi et al. PLoS One
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells
- (2014) Shweta Shrivastava et al. APOPTOSIS
- Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
- (2014) Jasmeet Chadha Singh et al. BREAST CANCER RESEARCH
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
- (2014) David S. Hong et al. CANCER
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
- (2014) P. Ganesan et al. MOLECULAR CANCER THERAPEUTICS
- Patient Involvement in Health Care Decision Making: A Review
- (2014) Shaghayegh Vahdat et al. Iranian Red Crescent Medical Journal
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Molecularly targeted therapies for metastatic triple-negative breast cancer
- (2013) Soley Bayraktar et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Tackling the Diversity of Triple-Negative Breast Cancer
- (2013) N. C. Turner et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Precision Oncology: An Overview
- (2013) Levi A. Garraway et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients
- (2013) Katarzyna Pogoda et al. MEDICAL ONCOLOGY
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- BEATRICE bevacizumab trial—every cloud has a silver lining
- (2013) Lisa Hutchinson Nature Reviews Clinical Oncology
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells
- (2012) Ming Qiu et al. CANCER LETTERS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Cancer and Radiation Therapy: Current Advances and Future Directions
- (2012) Rajamanickam Baskar et al. International Journal of Medical Sciences
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
- (2011) Mogens Bernsdorf et al. BREAST CANCER RESEARCH AND TREATMENT
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells
- (2010) Dong-Jun Peng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
- (2010) A Mailliez et al. BRITISH JOURNAL OF CANCER
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Genomic and personalized medicine: foundations and applications
- (2009) Geoffrey S. Ginsburg et al. Translational Research
- Emerging Patient-Driven Health Care Models: An Examination of Health Social Networks, Consumer Personalized Medicine and Quantified Self-Tracking
- (2009) Melanie Swan International Journal of Environmental Research and Public Health
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started